Tapentadol

1. 2026-10-19issueIssued info_card
2. 2026-09-07srcOpioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects
3. 2026-09-07srcPopulation Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain
4. 2026-09-07srcThe mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol
5. 2026-09-07srcTapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles
6. 2026-09-07srcIn vivo assessment of potential for UGT-inhibition-based drug-drug interaction between sorafenib and tapentadol
7. 2026-09-07srcEfficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease
8. 2026-09-07srcTapentadol hydrochloride: a centrally acting oral analgesic
9. 2026-09-07srcOpioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study
10. 2026-09-07srcNitric oxide modulates tapentadol antinociceptive tolerance and physical dependence
11. 2026-09-07srcA tapentadol related fatality: Case report with postmortem concentrations
12. 2026-09-07srcAssessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System
13. 2026-09-07srcThe antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice
14. 2026-09-07srcTapentadol - A representative of a new class of MOR-NRI analgesics
15. 2026-09-07srcSafety of tapentadol compared with other opioids in chronic pain treatment: network meta-analysis of randomized controlled and withdrawal trials
16. 2026-09-07srcAppropriate use of tapentadol: focus on the optimal tapering strategy
17. 2026-09-07srcTapentadol: navigating the complexities of abuse, patient safety & regulatory measures
18. 2026-09-07srcTapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy
19. 2026-09-07srcEvaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals
20. 2026-09-07srcCase report of a fatal intoxication by Nucynta
21. 2026-09-07srcTapentadol for the management of cancer pain in adults: an update
22. 2026-09-07srcOpioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome
23. 2026-09-07srcDeath due to apparent intravenous injection of tapentadol
24. 2026-09-07srcTapentadol results in less deterioration of gastrointestinal function and symptoms than standard opioid therapy in healthy male volunteers
25. 2026-09-07srcThe efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery
26. 2026-09-07srcA randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain
27. 2026-09-07srcSystematic review of tapentadol in chronic severe pain
28. 2026-09-07srcProbable Tapentadol-Associated Serotonin Syndrome After Overdose
29. 2026-09-07srcIn vitro and in vivo characterization of tapentadol metabolites
30. 2026-09-07srcComprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids
31. 2026-09-07srcPopulation pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain
32. 2026-09-07srcA randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy
33. 2026-09-07srcTramadol and Tapentadol Induce Conditioned Place Preference with a Differential Impact on Rewarding Memory and Incubation of Craving
34. 2026-09-07srcTapentadol: A Comprehensive Review of Its Role in Pain Management
35. 2026-09-07src(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties
36. 2026-09-07srcSchedules of controlled substances: placement of tapentadol into schedule II. Final rule.
37. 2026-09-07srcTapentadol - PubChem Compound Summary (CID 9838022)
38. 2026-09-07srcSchedules of controlled substances - placement of tapentadol into Schedule II - Canada Gazette 2015
39. 2026-09-07srcAustralian Public Assessment Report for Tapentadol (Palexia)
40. 2026-09-07srcTapentadol - UK Misuse of Drugs Act 1971 (Amendment) Order 2011
41. 2026-09-04issueIssued emergency
42. 2026-09-04issueIssued info_card
43. 2026-09-04issueIssued notice
44. 2026-08-19revisionr1.a1
45. 2026-07-03proposaldependence · taper
46. 2026-06-04proposal29 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
47. 2026-06-04publicationPublication — backfill
48. 2026-05-09revisionRevision 1
49. 2026-05-09absenceSearched PubMed for "tapentadol Tzschentke 2007 binding affinity pharmacological profile" — no results
50. 2026-05-09genGeneration — pipeline-v5 · with 2 morepipeline-v5
51. 2026-05-09rungeneration run

The same entries, as forms: six forms.